Showing results (51-60 of 59) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Journal of Biological Chemistry|June 1, 2000
Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689K Nogami, M Shima, K Hosokawa, et al.Journal of Thrombosis and Haemostasis : JTH|April 11, 2016
Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow-chamber systemK Nogami, K Ogiwara, K Yada, et al.Thrombosis Research|August 7, 1998
The role of platelet von Willebrand factor in the binding of factor VIII to activated plateletsH Suzuki, M Shima, S Kamisue, et al.The Journal of Biological Chemistry|October 16, 1999
Role of factor VIII C2 domain in factor VIII binding to factor XaK Nogami, M Shima, K Hosokawa, et al.British Journal of Haematology|October 16, 1999
Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effectK Nogami, M Shima, H Nakai, et al.Blood|February 7, 2001
Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysisK Nogami, M Shima, J C Giddings, et al.Thrombosis and Haemostasis|October 6, 2000
An alloantibody recognizing the FVIII A1 domain in a patient with CRM reduced haemophilia A due to deletion of a large portion of the A1 domain DNA sequenceM Shibata, M Shima, S Morichika, et al.Hematology (Amsterdam, Netherlands)|August 4, 2018
Common themes and challenges in hemophilia care: a multinational perspectiveJ Stoffman, N G Andersson, B Branchford, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|August 3, 2016
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitorsY Shinkoda, A Shirahata, K Fukutake, et al.Pageof 6